Eye surface disease study seeks to unlock vision predictors
NCT ID NCT07694817
First seen Jul 10, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This study aims to find which eye tests best predict vision in people with surface eye diseases like neurotrophic keratopathy and limbal stem cell deficiency. Researchers will collect data from standard exams and patient questionnaires from 1,000 adults. The goal is to identify key biomarkers for vision prognosis and improve personalized care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict vision outcomes and tailor treatments for people with eye surface diseases.
- What could go wrong
- This is an observational study, so it won't test a new treatment. The findings may not apply to all patients or lead to immediate changes in care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study will enroll adult patients (≥18 years old) of both sexes, representative of the population affected by OSD. No restrictions will be applied regarding ethnicity or socioeconomic background
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The participant is willing and able to provide written informed consent for study participation (prospective cohort). * Adult participants aged ≥18 years at the time of inclusion. * Clinically confirmed diagnosis of OSD, including but not limited to inflammatory keratopathies, neurotrophic keratopathy, exposure keratopathy, limbal stem cell deficiency, post-surgical or post-traumatic corneal alterations. * Measurable BSCVA obtained through standardized manifest refraction and ETDRS chart testing at baseline. * Available dataset for the diagnostic tests required by the study (e.g., corneal topography, pachymetry, confocal microscopy, corneal sensitivity testing, slit-lamp imaging, tear cytokine analysis, impression cytology). * Willingness and ability to attend follow-up visits and complete all study-related procedures according to the study schedule. Exclusion Criteria: * Change of retinal, optic nerve, or macular pathology that may affect best spectacle-corrected visual acuity independently of the cornea or ocular surface (e.g., age-related macular degeneration, diabetic macular edema, optic neuropathy) in the period of study * History of intraocular or corneal surgery within 3 months prior to baseline evaluation. * Active intraocular inflammation, glaucoma with uncontrolled intraocular pressure, or corneal conditions not compatible with accurate imaging or measurement (e.g., severe scarring, leukoma). * Uncontrolled systemic diseases that may impair vision or corneal health (e.g., advanced diabetes, autoimmune disease in active phase). * Inability or unwillingness to attend follow-up visits or complete study assessments. * Pregnant or breastfeeding women will not be enrolled, as hormonal fluctuations can alter tear film and ocular surface physiology
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cornea abnormality are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
IRCCS San Raffaele Scientific Institute
Milan, 20132, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells heal a rare eye ulcer?
- No-Stitch eye glue could spare patients pain and scarring
- Could your own blood heal a numb cornea? new trial tests Platelet-Rich eye drops
- Eye drops during surgery may be unnecessary, new study suggests
- Laser before eye implant may prevent glaucoma damage
- Could urine cells heal blindness? tiny trial begins